These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
261 related items for PubMed ID: 20184370
21. Hybrid inhibitors of phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR): design, synthesis, and superior antitumor activity of novel wortmannin-rapamycin conjugates. Ayral-Kaloustian S, Gu J, Lucas J, Cinque M, Gaydos C, Zask A, Chaudhary I, Wang J, Di L, Young M, Ruppen M, Mansour TS, Gibbons JJ, Yu K. J Med Chem; 2010 Jan 14; 53(1):452-9. PubMed ID: 19928864 [Abstract] [Full Text] [Related]
22. Synthesis and cytotoxicity of novel indirubin-5-carboxamides. Cheng X, Rasqué P, Vatter S, Merz KH, Eisenbrand G. Bioorg Med Chem; 2010 Jun 15; 18(12):4509-15. PubMed ID: 20488718 [Abstract] [Full Text] [Related]
23. Synthesis and antitumour activity of new muricatacin and goniofufurone analogues. Popsavin V, Srećo B, Krstić I, Popsavin M, Kojić V, Bogdanović G. Eur J Med Chem; 2006 Oct 15; 41(10):1217-22. PubMed ID: 16891043 [Abstract] [Full Text] [Related]
24. 4-Anilino-7-pyridyl-3-quinolinecarbonitriles as Src kinase inhibitors. Zhang N, Wu B, Boschelli DH, Golas JM, Boschelli F. Bioorg Med Chem Lett; 2009 Sep 01; 19(17):5071-4. PubMed ID: 19632113 [Abstract] [Full Text] [Related]
26. ATP non-competitive IGF-1 receptor kinase inhibitors as lead anti-neoplastic and anti-papilloma agents. Steiner L, Blum G, Friedmann Y, Levitzki A. Eur J Pharmacol; 2007 May 07; 562(1-2):1-11. PubMed ID: 17376430 [Abstract] [Full Text] [Related]
27. Synthesis and biological evaluation of selective and potent cyclin-dependent kinase inhibitors. N'gompaza-Diarra J, Bettayeb K, Gresh N, Meijer L, Oumata N. Eur J Med Chem; 2012 Oct 07; 56():210-6. PubMed ID: 22982525 [Abstract] [Full Text] [Related]
31. Evaluation of a series of naphthamides as potent, orally active vascular endothelial growth factor receptor-2 tyrosine kinase inhibitors. Weiss MM, Harmange JC, Polverino AJ, Bauer D, Berry L, Berry V, Borg G, Bready J, Chen D, Choquette D, Coxon A, DeMelfi T, Doerr N, Estrada J, Flynn J, Graceffa RF, Harriman SP, Kaufman S, La DS, Long A, Neervannan S, Patel VF, Potashman M, Regal K, Roveto PM, Schrag ML, Starnes C, Tasker A, Teffera Y, Whittington DA, Zanon R. J Med Chem; 2008 Mar 27; 51(6):1668-80. PubMed ID: 18324759 [Abstract] [Full Text] [Related]
38. Omega-alkoxy analogues of SAHA (vorinostat) as inhibitors of HDAC: a study of chain-length and stereochemical dependence. Hanessian S, Auzzas L, Giannini G, Marzi M, Cabri W, Barbarino M, Vesci L, Pisano C. Bioorg Med Chem Lett; 2007 Nov 15; 17(22):6261-5. PubMed ID: 17892933 [Abstract] [Full Text] [Related]
39. Design and synthesis of orally bioavailable benzimidazoles as Raf kinase inhibitors. Ramurthy S, Subramanian S, Aikawa M, Amiri P, Costales A, Dove J, Fong S, Jansen JM, Levine B, Ma S, McBride CM, Michaelian J, Pick T, Poon DJ, Girish S, Shafer CM, Stuart D, Sung L, Renhowe PA. J Med Chem; 2008 Nov 27; 51(22):7049-52. PubMed ID: 18942827 [Abstract] [Full Text] [Related]